The Biotin Enzyme Also Breaks Down Opioid Peptides — An Unexpected Dual Function | Research

The takeaway

Human serum biotinidase degrades enkephalins and short dynorphin with efficiency comparable to its biotin substrate — revealing an unexpected link between vitamin metabolism and opioid peptide regulation.

Equal efficiency for biotin and opioids
Biotinidase degrades enkephalins with kcat/Km values similar to its canonical biotin substrate

What the researchers found

Human serum biotinidase hydrolyzes enkephalins and dynorphin A (<10-mer) with kcat/Km values similar to its biotin substrate biocytin.

Why it matters

This reveals a previously unknown way the body controls opioid peptide levels in the blood. Biotinidase deficiency, a known genetic condition, might affect opioid peptide metabolism.

How the study worked

Purified human serum biotinidase was tested against various peptide substrates. Kinetic parameters (kcat, Km) were determined. Inhibition studies used various antibiotic inhibitors.

What this study cannot tell us

In vitro study using purified enzyme. Conditions differ from the complex blood environment. Clinical significance of this activity is unknown.

How to read the evidence

Preliminary in-vitro enzyme study. Demonstrates the dual activity but clinical significance is unknown.

When this study was published

Published in 1991. The broader implications for biotinidase deficiency patients remain understudied.

The bigger picture

Biotinidase deficiency is a known genetic condition treated with biotin supplementation. If this enzyme also controls opioid peptide levels, patients with biotinidase deficiency may have altered opioid signaling — potentially affecting pain sensitivity or mood.

Questions still open

Do biotinidase-deficient patients have altered opioid peptide levels?
Could biotinidase contribute to pain sensitivity differences between individuals?

Common questions

What is biotinidase?

An enzyme that releases biotin (vitamin B7) from proteins during digestion and recycling. Biotinidase deficiency is a genetic condition that can cause neurological problems if untreated.

Could biotinidase deficiency affect pain sensitivity?

Theoretically yes. If biotinidase normally degrades opioid peptides in the blood, its absence could lead to higher circulating opioid peptide levels — potentially affecting pain perception, though this hasn't been clinically tested.

Read the original research

Enkephalin hydrolysis by human serum biotinidase.

Biochimica et biophysica acta, 1074(3), 433-8

View on PubMed ↗

Citation

Oizumi, J; Hayakawa, K. (1991). Enkephalin hydrolysis by human serum biotinidase.. Biochimica et biophysica acta, 1074(3), 433-8.